We are live on ! Find out more

Adicet Bio

ACET

Market cap $83.8M

8.95 USD

-0.05

0.56%

At close Updated Aug 26, 4:00 PM EDT

1 day

-0.56%

5 days

-6.96%

1 month

11.04%

3 months

7.44%

6 months

22.27%

Year to date

1.47%

1 year

-24.09%

5 years

-92.74%

10 years

-99.53%

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Employees: 102

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 54.5%

Neutral 27.3%

Negative 18.2%

Zacks Investment Research

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

Here's Why You Should Add ACET Stock to Your Portfolio Now

Zacks Investment Research

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Adicet Bio: A Cheap Gamma Delta T-Cell Play

Adicet Bio offers a differentiated allogeneic gamma delta CAR-T platform targeting autoimmune diseases, trading below cash value with a pivotal readout imminent. Early prula-cel data in lupus nephritis showed 50% complete renal response and clean safety, supporting the curative CAR-T thesis versus chronic biologics. The upcoming 3Q 2026 readout on 22 patients is a binary catalyst; durability and long-term remission are critical for upside realization.

Adicet Bio: A Cheap Gamma Delta T-Cell Play

Zacks Investment Research

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet

The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE), Chief Executive Officer Chen Schor said at the 46th Annual Canaccord Genuity Growth Conference.

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

Zacks Investment Research

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2026. “At Adicet, we continue to advance prula-cel toward our next important clinical milestone, with a Phase 1 clinical update now expected in the third quarter of 2026. The additional f.

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.Details of the event are as follows:Date: Tuesday, August 11, 2026Time: 10:30.

Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

Zacks Investment Research

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference

Adicet Bio NASDAQ: ACET outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company's focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune disease and oncology.

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference

See News Rankings

Price charts implemented using Lightweight Charts™